title: [Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension].
abstract: OBJECTIVE
  To investigate the relationship among serum nitric oxide, D-dimer, blood pressure, dangerous states and target organ damage in essential hypertension and to evaluate the effects of enalapril and terazosin.
  
  
  METHODS
  Fifty-five patients were randomized into the enalapril group and terazosin group, each group receiving enalapril and terazosin respectively for 8 weeks. Serum nitric oxide and D-dimer were measured before and after the treatment.
  
  
  RESULTS
  Serum nitric oxide was lower (P < 0.001) but D-dimer was higher (P < 0.01) in the hypertensions than those in the controls. Serum nitric oxide and D-dimer were related to different levels of blood pressure, dangerous states and target organ damage; Both enalapril and terazosin could reduce the level of blood pressure; Both could increase the serum nitric oxide (P < 0.001) and decrease the D-dimer(P < 0.01).
  
  
  CONCLUSIONS
  Endothelial dysfunction and microthrombin can be found in the early stage of essential hypertension. Both enalapril and terazosin could improve the endothelial function and prothrombotic state by promoting the synthesis of nitric oxide.
authors.affiliation: Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Wei-ru
authors.initials: WR
authors.lastname: Zhang
authors.forename: Ming
authors.initials: M
authors.lastname: Sun
authors.forename: Jie-kun
authors.initials: JK
authors.lastname: Luo
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D009569:Nitric Oxide; D004656:Enalapril; C041226:Terazosin; D011224:Prazosin